Potential to use Deoxymabs to treat autoimmune diseases 

ASX Announcements

Patrys has announced that new data from preclinical studies using PAT-DX1 in animal models of anti neutrophil cytoplasmic antibody (ANCA) vasculitis will be presented at the 21st International Vasculitis Workshop in Barcelona next month.

Dr Kim O’Sullivan from Monash University will present on recent preclinical studies that demonstrate the potential to improve treatments for autoimmune diseases like ANCA vasculitis, an inflammatory condition caused by the buildup of of activated neutrophils and neutrophil extracellular traps (NETs) in small blood vessels. Current treatments increase the risk of infections, highlighting the need for safer therapies.

Patrys Chief Executive Officer and Managing Director, Dr James Campbell, said: 

“As GMP manufacturing for PAT-DX1 remains on track to commence in the current quarter, it is exciting to identify additional therapeutic opportunities for our deoxymab platform with promising future partnering and licensing opportunities for Patrys.”

Click here to read the ASX release.